COVID-19: Baricitinib in inpatient Therapy

被引：0
|
作者：
Meinrenken, Susanne
机构：
来源：
PNEUMOLOGIE | 2021年 / 75卷 / 05期
关键词：
D O I：
10.1055/a-1370-2260
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Verlauft eine COVID-19-Erkrankung schwer, liegt vermutlich eine Dysregulation des Immunsystems zugrunde. Therapeutisch kommt daher die Pravention einer Hyperinflammation in Betracht. Vor diesem Hintergrund konnte der selektive Januskinase-1/2-Inhibitor Baricitinib das klinische Outcome von Patienten mit COVID-19 verbessern. Positive Ergebnisse erwiesen sich in 3 Fallstudien; nun unternahm eine Forschergruppe eine kontrollierte Studie zu dieser Frage.
引用
收藏
页码：329 / 329
页数：1
相关论文
共 50 条
  • [1] Current Status of Baricitinib as a Repurposed Therapy for COVID-19
    Saber-Ayad, Maha
    Hammoudeh, Sarah
    Abu-Gharbieh, Eman
    Hamoudi, Rifat
    Tarazi, Hamadeh
    Al-Tel, Taleb H.
    Hamid, Qutayba
    [J]. PHARMACEUTICALS, 2021, 14 (07)
  • [2] Baricitinib Therapy in Covid-19 Pneumonia - An Unmet Need Fulfilled
    Goletti, Delia
    Cantini, Fabrizio
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09): : 867 - 869
  • [3] An EUA for Baricitinib (Olumiant) for COVID-19
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2020, 62 (1614): : 202 - 203
  • [4] Baricitinib: A chance to treat COVID-19?
    Lo Caputo, Sergio
    Corso, Gaetano
    Clerici, Mario
    Santantonio, Teresa Antonia
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (11) : 2343 - 2344
  • [5] Baricitinib for COVID-19: a suitable treatment?
    Favalli, Ennio G.
    Biggioggero, Martina
    Maioli, Gabriella
    Caporali, Roberto
    [J]. LANCET INFECTIOUS DISEASES, 2020, 20 (09): : 1012 - 1013
  • [6] Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab
    A. Cingolani
    A. M. Tummolo
    G. Montemurro
    E. Gremese
    L. Larosa
    M. C. Cipriani
    G. Pasciuto
    R. Liperoti
    R. Murri
    T. Pirronti
    R. Cauda
    M. Fantoni
    [J]. Infection, 2020, 48 : 767 - 771
  • [7] Efficacy of Combination Therapy with the JAK Inhibitor Baricitinib in the Treatment of COVID-19
    Brendan L. Thoms
    Jeanne Gosselin
    Bonita Libman
    Benjamin Littenberg
    Ralph C. Budd
    [J]. SN Comprehensive Clinical Medicine, 4 (1)
  • [8] Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab
    Cingolani, A.
    Tummolo, A. M.
    Montemurro, G.
    Gremese, E.
    Larosa, L.
    Cipriani, M. C.
    Pasciuto, G.
    Liperoti, R.
    Murri, R.
    Pirronti, T.
    Cauda, R.
    Fantoni, M.
    [J]. INFECTION, 2020, 48 (05) : 767 - 771
  • [9] Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
    Cantini, Fabrizio
    Niccoli, Laura
    Matarrese, Daniela
    Nicastri, Emanuele
    Stobbione, Paolo
    Goletti, Delia
    [J]. JOURNAL OF INFECTION, 2020, 81 (02) : 318 - 322
  • [10] Baricitinib: From Rheumatoid Arthritis to COVID-19
    Assadiasl, Sara
    Fatahi, Yousef
    Mosharmovahed, Banafsheh
    Mohebbi, Bahareh
    Nicknam, Mohammad Hossein
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (10): : 1274 - 1285
12345